Hospital

Pediatric patients with the variant were approximately 1.44 times more likely develop ALL compared with children who do not have the variant.

Investigators found that mRNA technology for the delivery of antibody therapeutics were used to target tau in Alzheimer disease and can be applied to other tau targets.

The ODD comes after AP303 presented meaningful improvements in renal survival in an ADPKD and the completion of the first study that evaluated healthy human participants.

As the full act will be enforced in November 2024, all medication dispensers must ensure they’re fully prepared.

The results displayed a dramatic reduction in the individuals’ tumors within days after single treatment.

Calder’s 3D Vaxlock technology attained 11 times more effective immune response, compared to typical comparator.

The authors believe that pancreatic enzyme therapy has potential in managing patient symptoms, altering the disease course, and the development of standardized care.

A study that analyzed data from 2000 to 2021 indicated improvements for both leukemia-free survival and overall survival for older patients with acute myeloid leukemia.

All 20 participants in a 12-month follow-up study attained acute success from ablation procedures.

Early treatment administration with this regimen also promoted a faster decrease in viral load and shorter viral shedding in patients with hematologic diseases who were positive for COVID-19.

The test scans whole blood samples from individual human donors for the 5 parasite species that can cause malaria in humans and detects Plasmodium RNA and DNA.

In December 2023, nipocalimab (Johnson & Johnson) was granted orphan drug designation for fetal neonatal alloimmune thrombocytopenia.

Pharmacists play a pivotal role working alongside the DEA and OIG in enforcing and preventing drug diversion nationally.

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

The orphan drug designation (ODD) comes after positive results from a phase 2 trial that showed cevidoplenib improved platelet counts by 63.6% and 40.9% in 2 different dose groups.

Zero relapses were reported among individuals that received ravulizumab-cwvz over the 73 weeks of treatment.

The indication is for adults and adolescents with moderate to severe immune compromise due to medical conditions or immunosuppressive medications and treatments.

Fortification with folic acid may be especially beneficial in countries that do not have mandated folic acid fortification regulations.

The test’s sensitivity in distinguishing colorectal cancer, in combination with real-world adherence, showed its ability to detect cancer at a curable stage.

An FDA executive discusses the Surgeon General’s recommendations for promoting mental health and wellbeing for employees in the workplace.

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Food pharmacies, in particular, can be a great opportunity for pharmacists to collaborate with other providers, improve access to nutritious foods, and find unique opportunities to counsel patients.

Shared decision making with patients is a key component of RSV vaccination, which can bring challenges and opportunities.

Pharmacogenomics could help streamline prescribing and dosing for psychiatric medications, avoiding the trial-and-error process common with these medications.

Pharmacists can educate patients on current clinical evidence of cannabis’s therapeutic benefit, as well as cannabis’s complexities, risks, and potential adverse effects.

Positive data were presented at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Disease in Cape Town, South Africa.

Identifying the best uses for these tools, whether in patient education, data collection, improving efficiencies, or other uses, could significantly improve the future of pharmacy.

When considering community-acquired pneumonia alone, the PCR test identified 113 bacterial detections compared with 57 for the standard of care test.

The data comes from 2 phase 4 trials, ENABLE and EMPOWER, which evaluated lanadelumab and the outcomes of treatment in adolescents with hereditary angioedema.

As data continue to develop in this arena, β-lactam therapeutic drug monitoring is likely to become more routine, as it has with drugs like vancomycin and the aminoglycosides.